Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatol Treat. 2018;29:220–9.

Article  CAS  Google Scholar 

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate to severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:639–47.

Article  PubMed  PubMed Central  Google Scholar 

Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8:571–9.

Article  PubMed  PubMed Central  Google Scholar 

Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–93.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60-9.e9.

Article  CAS  PubMed  Google Scholar 

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate to severe plaque psoriasis. N Engl J Med. 2016;375:345–56.

Article  CAS  PubMed  Google Scholar 

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371:326–38.

Article  PubMed  Google Scholar 

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–28.

Article  CAS  PubMed  Google Scholar 

Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, et al. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study. J Dermatol. 2019;46:752–8.

Article  CAS  PubMed  Google Scholar 

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–9.

Article  PubMed  Google Scholar 

Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70:146–67.

Article  PubMed  Google Scholar 

European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf. Accessed 10 Jun 2021.

Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75:77-82.e7.

Article  PubMed  Google Scholar 

Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(871–81):e1-30.

Google Scholar 

Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.

Article  CAS  PubMed  Google Scholar 

Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol. 2016;9:S12–6.

PubMed  PubMed Central  Google Scholar 

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–48.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–73.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73:110–20.

Article  CAS  PubMed  Google Scholar 

Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72.

Article  CAS  PubMed  Google Scholar 

Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40.

Article  PubMed  Google Scholar 

Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.

Article  PubMed  Google Scholar 

Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM, et al. Pattern of response in patients with moderate to severe psoriasis treated with etanercept. Br J Dermatol. 2015;172:230–8.

Article  CAS  PubMed  Google Scholar 

Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate to severe psoriasis. J Drugs Dermatol. 2014;13:554–62.

CAS  PubMed  Google Scholar 

Sojević Timotijević Z, Majcan P, Trajković G, Relić M, Novaković T, Mirković M, et al. The impact of changes in Psoriasis Area and Severity Index by body region on quality of life in patients with psoriasis. Acta Dermatovenerol Croat. 2017;25:215–22.

PubMed  Google Scholar